**Supplementary Table 2**: Indications for EEN by disease location:

Which of the following indications would you consider EEN to be the first line therapy in your practice (include all that apply)?

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| Disease Location | Total | Canada | US | UK | Spain | E-O |
| Paris L1 | **88%** | 90% | 95% | 100% | 83% | 92% |
| Paris L2 | **52%** | 33% | 26% | 73% | 65% | 61% |
| Paris L3 | **91%** | 86% | 84% | 100% | 98% | 84% |
| Paris L1 + L4a or L4b | **74%** | 76% | 63% | 64% | 70% | 89% |
| Paris L2 + L4a or L4b | **56%** | 43% | 42% | 55% | 58% | 71% |
| Paris L3 + L4a or L4b | **72%** | 67% | 63% | 64% | 70% | 87% |
| L1 + significant perianal disease | **30%** | 24% | 32% | 55% | 20% | 32% |
| L2 + significant perianal disease | **23%** | 14% | 11% | 45% | 13% | 29% |
| L3 + significant perianal disease | **29%** | 29% | 32% | 45% | 15% | 32% |
| Selective cases of ulcerative colitis  | **6%** | 5% | 5% | 0% | 5% | 11% |

E-O: Europe-Other (excludes UK and Spain; includes Israel).